Article

Viewpoint: The Current Advances and Future Optimization of Blood-based Tumor Mutation Burden as a Biomarker for Cancer Immunotherapy

2021-03-02

Abstract excerpt

Instead of tissue-based detection, blood-based tumor mutation burden (bTMB) is becoming an alternative promising alternate to predict the response of immune checkpoint inhibitor in cancers, especially non-small-cell lung cancer. Although bTMB is more convenient and less invasive, many evidences identified its limited predictive ability and less accurate discrimination of candidates to receive immunotherapy. Severa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dff2763d-793b-53dc-8d0e-82d256037dbd
DOI: 10.20944/preprints202103.0113.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Viewpoint: The Current Advances and Future Optimization of Blood-based Tumor Mutation Burden as a Biomarker for Cancer ImmunotherapyDOI 10.20944/preprints202103.0113.v1Read

New methodology of TMB assessment from tissue and liquid biopsy in NSCLC.Semantic proximity Read

Expert consensus on the detection and clinical application of tumor mutational burden.Semantic proximity Read

Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-makingSemantic proximity Read

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read

Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shedSemantic proximity Read

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.Semantic proximity Read

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ ageSemantic proximity Read

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.Semantic proximity Read

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read